Monopar Therapeutics (NASDAQ:MNPR) Director Kim Tsuchimoto Sells 2,891 Shares of Company Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 2,891 shares of the stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $71.26, for a total value of $206,012.66. Following the completion of the transaction, the director directly owned 1,199 shares in the company, valued at $85,440.74. This trade represents a 70.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Price Performance

Shares of NASDAQ MNPR opened at $72.81 on Thursday. The company has a market capitalization of $488.56 million, a price-to-earnings ratio of -33.55 and a beta of 1.62. The business has a 50-day moving average of $88.66 and a two-hundred day moving average of $77.40. Monopar Therapeutics Inc. has a 1 year low of $50.07 and a 1 year high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.02. As a group, equities research analysts expect that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in shares of Monopar Therapeutics in the second quarter valued at approximately $7,124,000. Siren L.L.C. grew its position in shares of Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after acquiring an additional 53,336 shares during the period. ADAR1 Capital Management LLC increased its holdings in shares of Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after acquiring an additional 30,370 shares during the period. Finally, Walleye Capital LLC purchased a new stake in Monopar Therapeutics in the 1st quarter valued at $3,458,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, October 15th. Cantor Fitzgerald cut shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the company from $109.00 to $119.00 in a report on Thursday, August 13th. HC Wainwright increased their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Finally, Barclays reiterated an “overweight” rating and set a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Monopar Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $122.00.

Key Headlines Impacting Monopar Therapeutics

Here are the key news stories impacting Monopar Therapeutics this week:

• Neutral Sentiment: Monopar is projected to announce quarterly earnings on Thursday. The report could give investors an update on the company’s performance; no results or estimates are detailed in the article. Monopar Therapeutics projected to announce quarterly earnings
• Neutral Sentiment: A separate article raises the question of what investment firms think about MNPR, but the provided information does not specify any firms’ ratings, price targets, or recent actions. What investment firms are thinking about MNPR
• Negative Sentiment: Directors reported selling shares: Kim Tsuchimoto sold 2,891 shares on Nov. 4 and 1,199 on Nov. 2, while Raymond Anderson sold 3,142 shares on Nov. 2. The sales reduced their reported holdings and could concern investors, although the transactions were made under pre-arranged Rule 10b5-1 plans. SEC filing for director transactions

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.